Is Universal Patient Access to Fulvestrant in Hormone Receptor-positive Advanced Breast Cancer Justified? A UK Retrospective Multicentre Study

Autor:	A. Guppy, Alicia Okines, A. Lerner, Apostolos Konstantis, Judy King, Daire Hanna, E. Takeuchi, Rebecca Roylance, B. Sanderson, Fharat Raja, K. Keshwani, F. Rehman, E. Spurrell, R. Murphy, C. Westbury, E. Sharkey, R.E. Board, Michael Flynn
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Fulvestrant business.industry Advanced breast Cancer medicine.disease Hormone receptor Internal medicine medicine Radiology Nuclear Medicine and imaging business medicine.drug
Zdroj:	Clinical Oncology. 32:e167
ISSN:	0936-6555
DOI:	10.1016/j.clon.2020.02.009
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a3ce7fb5d61bf1a113e8dc6e358e5fc7 https://doi.org/10.1016/j.clon.2020.02.009 Zobrazit plný text záznamu Full Text from ScienceDirect